30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

Documenti analoghi

• Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
  di: Cristina De Ramón, et al.
  Pubblicazione: (2024)
• High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
  di: Andrea Manubens, et al.
  Pubblicazione: (2025)
• Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
  di: Ola Landgren, et al.
  Pubblicazione: (2025)
• European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
  di: Niccolò Bolli, et al.
  Pubblicazione: (2025)
• Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
  di: Kazimierz Groen, et al.
  Pubblicazione: (2025)